I guess many, myself included view(ed) them as a Biotech company and they are not, they are a Holding Company that deals in acquiring assets in the biotech industry for the purpose of improving and selling. So absent revenues from being unable to sell these assets or not wanting to because they feel the offer is not good enough they have no other choice but to continue to authorize and issue shares that keep the company afloat and of course dilute the share price. The losses on paper are tough and it has been an expensive lesson one I will not forget in the future.
Yes, Lympro the gold standard. I guess nobody wants the gold standard as it has been 6 months and no news of any revenue. Really do you think Lympro was pumped up? And really what happen to all those NDA's that GC was working on?
News 
Market Data 
Discover 
